SEI Investments’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-39,380
| Closed | -$2.64M | – | 2502 |
|
|
2019
Q3 | $2.64M | Sell |
39,380
-476
| -1% | -$32.7K | 0.01% | 1210 |
|
|
2019
Q2 | $2.29M | Sell |
39,856
-12,963
| -25% | -$768K | 0.01% | 1276 |
|
|
2019
Q1 | $3.68M | Buy |
52,819
+3,834
| +8% | +$284K | 0.01% | 1052 |
|
|
2018
Q4 | $3.33M | Buy |
48,985
+16,952
| +53% | +$1.19M | 0.01% | 1098 |
|
|
2018
Q3 | $2.23M | Buy |
32,033
+6,586
| +26% | +$385K | 0.01% | 1226 |
|
|
2018
Q2 | $1.28M | Buy |
25,447
+24,769
| +3,653% | +$983K | ﹤0.01% | 1489 |
|
|
2018
Q1 | $22K | Buy |
678
+417
| +160% | +$13.8K | ﹤0.01% | 2630 |
|
|
2017
Q4 | $9K | Buy |
261
+148
| +131% | +$4.72K | ﹤0.01% | 2835 |
|
|
2017
Q3 | $4K | Buy |
+113
| New | +$3.56K | ﹤0.01% | 2901 |
|
|
2016
Q3 | – | Sell |
-2
| Closed | – | – | 3050 |
|
|
2016
Q2 | $0 | Sell |
2
-44
| -96% | -$1.17K | ﹤0.01% | 2811 |
|
|
2016
Q1 | $1K | Buy |
+46
| New | +$1.26K | ﹤0.01% | 2469 |
|
SEI Investments's GHDX Position: Q4 2019 in Review
SEI Investments sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 39,380 shares — an estimated $2.64M sold.
SEI Investments first reported a position in GHDX in Q1 2016 and held it in 11 quarters. The position peaked at $3.68M in Q1 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- SEI Investments reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- SEI Investments sold 39,380 Genomic Health, Inc. shares in Q4 2019, an estimated $2.64M.
- SEI Investments first reported a position in Genomic Health, Inc. in Q1 2016 and held it in 11 quarters.
- SEI Investments's Genomic Health, Inc. position peaked at $3.68M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on SEI Investments's 13F filing for Q4 2019, filed 6 Feb 2020.